Amsterdam-based Life Sciences Partners LSP announced that the LSP Health Economics Fund 2 is now the largest European investment fund dedicated to healthcare innovation. An additional €280m was raised from the European Investment Fund, health insurance companies, and institutional investors.
Reportedly, the fund will look to invest in around 15 private companies with innovative products “on the market or very close to market introduction”. Rudy Dekeyser, LSP partner, said to Digital Health News that their focus areas are in drug compliance, remote monitoring, big data analytics and clinical software. Further caveats: companies must “convince us that there is a clear path towards the integration of their innovative product in the complicated healthcare ecosystem, has to know who will pay for their product or services and should have access to the necessary partners for broad implementation of their product in the market.”
This adds to end-of-year UK and European announcements of early-stage life sciences and healthcare innovation funding. As reported in Digital Health News: the UK government’s life sciences industry partnership to advance medical technology in Britain (Digital Health News); Wayra UK (Telefónica) and Merck Sharp & Dohme’s Velocity Health £68,000 healthcare accelerator program for machine learning/AI start-ups. LSP release